ACTU DEFA14A SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

ACTU ▼ -39.13% at T+20d

NEUTRAL call ✗ call lost -39.13% · α vs SPY -41.91% · entry $2.99 → $1.82

Next anchor: T+60d in 7w

Last close $2.02 (close Jun 12) · -32.44% from $2.99 entry

Entry anchored
May 6, 09:50 AM ET
via Databento tick

T+1d

+11.71%

call +11.71% · α +12.04%

$3.34

settled 6w ago

T+5d

-3.34%

call -3.34% · α -4.48%

$2.89

settled 5w ago

T+20d

-39.13%

call -39.13% · α -41.91%

$1.82

settled 11d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

Actuate Therapeutics filed a proxy supplement disclosing the appointment of Dr. Martin H. Huber as an independent director, expanding the board from 7 to 8 members. This adds depth to the board with a seasoned biopharma executive, but the timing near a proxy fight suggests it may be a response to activist pressure. No material financial impact, but the move could influence the upcoming May 21 annual meeting vote.

Actionable Insight

Monitor the annual meeting on May 21 for any dissident proposals or changes in board composition. The appointment may reduce activist pressure, but the proxy fight context remains active—watch for further filings or investor communications.

Key Facts

Board expanded from 7 to 8 directors; Dr. Huber appointed effective May 1, 2026.
Dr. Huber is an independent director with extensive executive and clinical experience (ex-CEO of Mersana, ex-CMO of TESARO, ex-VP at Merck).
He received an initial grant of 30,000 stock options (3-year vest) and an annual retainer of $44,000.
Additional consulting agreement provides quarterly fee of $3,000 for R&D advisory services.
The supplement is in connection with the 2026 Annual Meeting scheduled for May 21, 2026.

Financial Impact

No material financial impact; compensation is standard non-employee director program.

Risk Factors

Potential for ongoing proxy contest if activist demands are not fully addressed.
New director's influence on R&D strategy could shift pipeline priorities.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

90% bullish (10 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

Document	Accession Number
DEFA14A Filing (Primary)	0001683168-26-003517
Document: 0001683168-26-003517-index-headers.html	0001683168-26-003517
Document: 0001683168-26-003517-index.html	0001683168-26-003517
Document: 0001683168-26-003517.txt	0001683168-26-003517

6 reports for ACTU

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for ACTU — sortable, filterable
	Type				Now
Jun 9, 2026 5d ago	Press Release BULLISH ★ 7/10	$1.82 awaiting T+5	awaiting T+5	—	$2.02 (+10.99%)
May 11, 2026 4w ago	8-K MIXED ★ 7/10	$2.89 $2.43	▼ −15.92%	▼ −15.99%	$2.02 (−30.10%)
May 6, 2026 5w ago	DEFA14A NEUTRAL ★ 4/10	$2.99 $2.89	▼ −3.34%	▼ −4.48%	$2.02 (−32.44%)
May 6, 2026 5w ago	8-K NEUTRAL ★ 4/10	$2.99 $2.89	▼ −3.34%	▼ −4.48%	$2.02 (−32.44%)
Apr 14, 2026 8w ago	Press Release BULLISH ★ 8/10	$2.08 $2.27	▲ +8.89%	▲ +7.50%	$2.02 (−2.88%)
Mar 9, 2026 13w ago	Press Release NEUTRAL ★ 4/10	$2.95 $2.68	▼ −9.00%	▼ −7.64%	$2.02 (−31.41%)

US Market Status

Market Closed — Opens in 4h 17m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access